Literature DB >> 10579797

Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines.

J Jongsma1, M H Oomen, M A Noordzij, J C Romijn, T H van Der Kwast, F H Schröder, G J van Steenbrugge.   

Abstract

BACKGROUND: Androgen-independent growth leads to progressive prostate cancer after androgen-ablation therapy. This may be caused by altered specificity of the androgen receptor (AR), by ligand-independent stimulation of the AR, or by paracrine growth modulation by neuropeptides secreted by neuroendocrine (NE) cells.
METHODS: We established and characterized the androgen-independent FGC-DCC from the androgen-dependent LNCaP fast growing colony (FGC) cell line. The androgen-independent DU-145, FGC-DCC, and PC-3, and the androgen-dependent LNCaP and PC-346C cell lines were used to study growth modulation of gastrin-releasing peptide (GRP), calcitonin (CT), serotonin (5-HT), and vasoactive intestinal peptide (VIP) by (3)H-thymidine incorporation. Specificity of the growth-modulating effects was tested with the anti-GRP monoclonal antibody 2A11 and induction of cAMP by neuropeptides.
RESULTS: Androgen-independent growth stimulation by neuropeptides was shown in DU-145 and PC-346C. 2A11 inhibited GRP-induced (3)H-thymidine incorporation in DU-145 and PC-346C and inhibited proliferation of the FGC-DCC and PC-3 cell lines. With some exceptions, cAMP induction paralleled growth stimulation. Dideoxyadenosine (DDA) inhibited the GRP-induced growth effect in DU-145 and PC-346C, whereas oxadiazoloquinoxaline-1-one (ODQ) had no effect on (3)H-thymidine incorporation. None of the neuropeptides stimulated growth of LNCaP, FGC-DCC, or PC-3.
CONCLUSIONS: GRP-induced growth of DU-145 and PC-346C was specific and cAMP-mediated. Androgen-independent growth of FGC-DCC cells was mainly due to an induction of Bcl-2 expression and possibly through the activation of an autocrine and NE-like pathway, as has been shown also for the PC-3 cell line. Growth induction of non-NE cells by neuropeptides could be a possible role for NE cells in clinical prostate cancer. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10579797     DOI: 10.1002/(sici)1097-0045(20000101)42:1<34::aid-pros5>3.0.co;2-2

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  13 in total

1.  Antitumorigenic actions of growth hormone-releasing hormone antagonists.

Authors:  R D Kineman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-18       Impact factor: 11.205

Review 2.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

3.  TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.

Authors:  Z Mounir; F Lin; V G Lin; J M Korn; Y Yu; R Valdez; O H Aina; G Buchwalter; A B Jaffe; M Korpal; P Zhu; M Brown; R D Cardiff; J L Rocnik; Y Yang; R Pagliarini
Journal:  Oncogene       Date:  2014-09-29       Impact factor: 9.867

Review 4.  Neuroendocrine Differentiation in Prostate Cancer: Emerging Biology, Models, and Therapies.

Authors:  Loredana Puca; Panagiotis J Vlachostergios; Himisha Beltran
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

Review 5.  Endo/exo-proteolysis in neoplastic progression and metastasis.

Authors:  Abdel-Majid Khatib; Daniel Bassi; Geraldine Siegfried; Andres J P Klein-Szanto; L'Houcine Ouafik
Journal:  J Mol Med (Berl)       Date:  2005-08-26       Impact factor: 4.599

Review 6.  Mechanisms of the development of androgen independence in prostate cancer.

Authors:  Alan So; Martin Gleave; Antonio Hurtado-Col; Colleen Nelson
Journal:  World J Urol       Date:  2005-01-27       Impact factor: 4.226

7.  VIP and PACAP are autocrine factors that protect the androgen-independent prostate cancer cell line PC-3 from apoptosis induced by serum withdrawal.

Authors:  Irene Gutiérrez-Cañas; Nieves Rodríguez-Henche; Oscar Bolaños; María J Carmena; Juan C Prieto; María G Juarranz
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

8.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

9.  Immunohistochemical detection of gastrin releasing peptide in patients with prostate cancer.

Authors:  Constantinos Constantinides; Andreas C Lazaris; Konstantinos N Haritopoulos; Dimitrios Pantazopoulos; Michalis Chrisofos; Aris Giannopoulos
Journal:  World J Urol       Date:  2003-07-05       Impact factor: 4.226

10.  Isolation and identification of L-dopa decarboxylase as a protein that binds to and enhances transcriptional activity of the androgen receptor using the repressed transactivator yeast two-hybrid system.

Authors:  Latif A Wafa; Helen Cheng; Mira A Rao; Colleen C Nelson; Michael Cox; Martin Hirst; Ivan Sadowski; Paul S Rennie
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.